Search for a trial

COMPRehensive assessment of prevalence, risk factors and mechanisms of impaired medical and psychosocial health outcomes among Adolescents and Young Adults with cancer: the prospective observational COMPRAYA cohort study

To examine the prevalence, risk factors and mechanisms of impaired health outcomes (short- and long-term medical and psychosocial effects and late effects) over time among a population-based sample of AYA cancer patients.Primary Objective: - To…

Personalized elective neck irradiation guided by sentinel lymph node biopsy in patients with squamous cell carcinoma of the oropharynx, larynx or hypopharynx with a clinically negative neck: (chemo)radiotherapy to the PRIMary tumor Only. The PRIMO study.

To compare safety and efficacy of treatment with sentinel lymph node biopsy guided elective neck irradiation versus standard elective neck irradiation in patients receiving definitive (chemo)radiotherapy for squamous cell carcinoma of the…

Early detection of symptoms using digital patient-reported symptom monitoring and a Fitbit to optimize care in metastatic breast cancer (SYMPHA, BOOG 2024-01).

This study aims to determine the effect of real-time symptom monitoring on HRQoL in patients with mBC who start first-line chemo(immune)therapy. Further objectives include analyzing the effect of PRS monitoring on physical functioning, the severity…

A short scheme of preoperative radiotherapy for soft tissue sarcomas

to compare the short-term toxicity of the conventional schedule of 25 x 2 Gy, once daily fractionation in a five-week Overall Treatment Time (OTT) to 14 x 3 Gy, once daily fractionation in a three-week OTT, with respect to the rate of postoperative…

TAO – Towards optimal (neo)adjuvant systemic therapy of stage III triple-negative breast cancer

The main aim of the current study is to adequately assess HRQoL in patients with stage III TNBC receiving current standard (neo)adjuvant systemic therapy. These outcomes can then be used as a HRQoL benchmark for patients with stage III TNBC treated…

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

Primary Objectives:Associated pharmaceutical trial:To compare the efficacy of disitamab vedotin in combination with pembrolizumab to chemotherapy as first-line treatment in participants with advanced UC that expresses HER2Clinical…